2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 448

Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice

Pain Mechanisms – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 692

TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 233

TNF Inhibitors: Prevalence of Use and Predictors of Treatment Non-Persistence in the 2011-2016 Medicare Population

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 63

TNF-α Blockade Incompletely Reverses Inflammatory Pulmonary Pathology in the TNF-Transgenic Mouse Model of Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 767

Tobacco and Systemic Lupus Erythematosus Relationships: Pay Attention to the Retina!

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 49

Tofacitinib Facilitates the Expansion of Myeloid-Dirived Suppressor Cells and Ameliorates Interstitial Lung Disease in SKG Mice

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 27

Top-Down Proteomics Coupled with Antibody Sequencing from Single B Cells Reveals a Monoclonal Anti-Sm Clone Present in the Serum of an SLE Patient over Three Years

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 444

Trajectories of Sport or Recreational Activities over Eight Years and Associated Factors in Persons at Risk for Knee Osteoarthritis

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 803

Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 556

Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 23

Treatment with Immune Checkpoint Inhibitors and the Development of Autoantibodies

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 434

Trends in Procedure Type, Patient Characteristics, and Outcomes Among Persons with Knee Osteoarthritis Undergoing Bariatric Surgery, 2005-2014

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 498

Trends in the Incidence of Cardiovascular Diseases in Patients with Rheumatoid Arthritis in Spain: A National Observational Cohort Study of Hospital Discharges

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 493

Trends in the Incidence of SOLID Tumors in Patients with Rheumatoid Arthritis in Spain. a National Observational Cohort Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 695

Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.